Neos Therapeutics Inc (NASDAQ:NEOS) shares traded down 8.2% during trading on Thursday . The stock traded as low as $2.56 and last traded at $2.58. 750,560 shares traded hands during mid-day trading, an increase of 137% from the average session volume of 316,458 shares. The stock had previously closed at $2.81.
Several research analysts recently commented on the company. ValuEngine upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 12th. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a research report on Wednesday, August 8th. Finally, Wells Fargo & Co dropped their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $15.50.
The stock has a market capitalization of $77.15 million, a P/E ratio of -0.96 and a beta of 0.44.
In other Neos Therapeutics news, Director Alan L. Heller bought 43,478 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was acquired at an average price of $2.30 per share, for a total transaction of $99,999.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.40% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its stake in shares of Neos Therapeutics by 162.5% during the third quarter. JPMorgan Chase & Co. now owns 267,417 shares of the company’s stock valued at $1,297,000 after acquiring an additional 165,555 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in shares of Neos Therapeutics by 22.1% during the third quarter. Essex Investment Management Co. LLC now owns 285,716 shares of the company’s stock valued at $1,386,000 after acquiring an additional 51,744 shares in the last quarter. Northern Trust Corp raised its stake in shares of Neos Therapeutics by 10.7% during the second quarter. Northern Trust Corp now owns 294,678 shares of the company’s stock valued at $1,842,000 after acquiring an additional 28,378 shares in the last quarter. Millennium Management LLC raised its stake in shares of Neos Therapeutics by 171.9% during the second quarter. Millennium Management LLC now owns 170,045 shares of the company’s stock valued at $1,063,000 after acquiring an additional 107,515 shares in the last quarter. Finally, Nexthera Capital LP bought a new stake in shares of Neos Therapeutics during the second quarter valued at approximately $2,369,000. Institutional investors and hedge funds own 46.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally published by WKRB News and is the property of of WKRB News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.wkrb13.com/2018/11/09/neos-therapeutics-neos-shares-down-8-2.html.
Neos Therapeutics Company Profile (NASDAQ:NEOS)
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Story: Index Funds
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.